Lupin obtains tentative nod for vaccine to cure toenail fungal infection disease

Lupin Limited informed that it has received tentative approval from United States Food & Drug Administration for Efinaconazole topical solution, 10 per cent to market a generic equivalent of Jublia® topical solution, 10 per cent of Bausch Health Americas, Inc. This solution is used to cure Onychomycosis, a fungal infection caused in nails. 

The said solution would be used in the topical treatment of Onychomycosis of the toenail(s) caused due to the Trichophyton rubrum and Trichophyton mentagrophytes. The symptoms of Onychomycosis include white or yellow nail discoloration, thickening of the nail as well as the separation of the nail from the nail bed. It can affect toenails or fingernails but more commonly, the former part. The annual sales of Efinaconazole Topical Solution, 10 per cent, (RLD: Jublia®) were estimated to be USD 222.9 million in the US. 

Lupin Ltd is the third-largest pharmaceutical company in the US by way of prescriptions and the fifth-largest in India in terms of global revenue. It has headquarters in Mumbai and is engaged into the business of producing, developing, and marketing a range of branded & generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) across the world.  

Meanwhile, in the second half of the trading session on Monday, the company, in another update, announced that it has received approval for the launch of Meloxicam Capsules, 5 mg & 10 mg from United States Food & Drug Administration. The mentioned capsules are generic equivalent of Vivlodex® capsules, 5 mg & 10 mg, of Zyla Life Sciences US, Inc. These capsules are used for the medication of Osteoarthritis (OA) pain, a type of arthritis that occurs when flexible tissue at the end of bones wears down. Meloxicam Capsules (RLD: Vivlodex®) reported annual sales of approximately USD 11 million in the US (IQVIA MAT October 2020). 

At 2.17 pm on Monday, the stock of Lupin was trading at Rs 983.90, up by 0.79 per cent against its previous close of Rs 976.15. Its 52-week high is Rs 1,121.85 while the 52-week low is Rs 505.00 on BSE.